Health risk assessments shed light on early predictors of depression

Johnson & JohnsonA new research study supported by Johnson & Johnson Health and Wellness Solutions suggests that health risk assessments (HRAs) can help predict depression in segments of the population who may not be routinely screened in traditional healthcare settings. HRAs are often used by employers and health plans to identify modifiable health risks, such as stress, sleep and quality of life. This new study demonstrates the value of HRAs to identify predictors for depression.

The research study found that about 25 percent of the HRA participants experienced mild or "sub-threshold" symptoms of depression. One in five of them deteriorated over time to more significant distress, as measured by an increase in symptoms of depression. These individuals had a similar level of symptoms as individuals with chronic depression at the end of the study and experienced an even greater level of functional impairment in their day to day lives. The study also identified key risk factors that predicted both positive and negative changes in depressive symptoms. As employers look for ways to increase the health and productivity of their employees, the value of further research using HRAs to study populations at risk for depression is notable.

"This study indicates that HRAs can be a useful and powerful analytic tool to identify and begin early intervention for at-risk populations," said Heather Cole-Lewis, PhD, Behavioral Scientist, Johnson & Johnson Health and Wellness Solutions. "There is a substantial group of people among our HRA participants who have depressive symptoms but might not necessarily meet criteria indicating a need for clinical management. We know now that a significant portion of them are at risk of progressing to levels of distress and experiencing considerable productivity impairment in the process. We need to find ways to reach these individuals before they experience such difficulties."

Symptoms of depression have been shown to decrease daily function and productivity, and play a significant role in determining the success of population health management efforts. Given that 53 percent of large U.S. employers and 23 percent of small U.S. employers use HRAs with employees, the opportunity for further longitudinal data analysis in large populations is compelling and has the potential to facilitate earlier interventions for preventing depression.

"HRAs have been used for a long time to look at the health information for populations at large. One of the most useful takeaways from this study is that HRAs can help identify individuals with subthreshold depressive symptoms who may deteriorate over time, as well as those who are at risk of chronic depression," said Jennifer Turgiss, Vice President, Behavioral Science & Advanced Analytics, Johnson & Johnson Health and Wellness Solutions. "We at Johnson & Johnson recommend that health plan providers, including self-insured employers, consider using HRAs to help identify subthreshold individuals and explore new methods to reach them as early as possible with solutions that build important skills, such as resilience, to help manage and improve low-levels of depression."

About the Study
The study, "Trajectories of Depressive Symptoms among Online Health Risk Assessment Participants," was published in the Journal of Medical Internet Research on March 31, 2017. It was conducted by Johnson & Johnson Health and Wellness Solutions as part of the company's commitment to health and wellbeing. The study used data collected from the online HRAs of 22,963 adult participants.

The study used a growth mixture model to examine longitudinal trends in depressive symptoms of voluntary HRA adult participants. The study identified five classes of depressive symptom trajectories: "minimal depression" (scores were consistently low across time), "low risk" (scores remained sub-threshold over time), "deteriorating" (scores began at sub-threshold but approached severe depression over time), "chronic" (scores remained in highly depressive category over time) and "remitting" (moderate depression to start but crossed into minimal by the end).

About Johnson & Johnson Health and Wellness Solutions
Johnson & Johnson Health and Wellness Solutions, Inc. serves as the center of excellence for Johnson & Johnson's capabilities in behavior modification, patient/consumer experience, health care analytics and coaching platforms. It offers an integrated portfolio of solutions to cover a broad spectrum of health management - from wellness and prevention, to behavioral health, to chronic disease support. These solutions are designed to improve outcomes, control costs and enhance the patient and consumer experience. Its guiding purpose is to invest energy toward vibrant and longer lives.

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...